[go: up one dir, main page]

AU2001233957A1 - Proteins, genes and their use for diagnosis and treatment of bipolar affective disorder (bad) and unipolar depression - Google Patents

Proteins, genes and their use for diagnosis and treatment of bipolar affective disorder (bad) and unipolar depression

Info

Publication number
AU2001233957A1
AU2001233957A1 AU2001233957A AU3395701A AU2001233957A1 AU 2001233957 A1 AU2001233957 A1 AU 2001233957A1 AU 2001233957 A AU2001233957 A AU 2001233957A AU 3395701 A AU3395701 A AU 3395701A AU 2001233957 A1 AU2001233957 A1 AU 2001233957A1
Authority
AU
Australia
Prior art keywords
genes
diagnosis
bad
proteins
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001233957A
Inventor
Herath Mudiyanselage Athula Chandrasiri Herath
Rajesh Bhikhu Parekh
Christian Rohlff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Glycosciences UK Ltd
Original Assignee
Oxford Glycosciences UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0004412A external-priority patent/GB0004412D0/en
Priority claimed from GB0030050A external-priority patent/GB0030050D0/en
Application filed by Oxford Glycosciences UK Ltd filed Critical Oxford Glycosciences UK Ltd
Publication of AU2001233957A1 publication Critical patent/AU2001233957A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/304—Mood disorders, e.g. bipolar, depression

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2001233957A 2000-02-24 2001-02-23 Proteins, genes and their use for diagnosis and treatment of bipolar affective disorder (bad) and unipolar depression Abandoned AU2001233957A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0004412 2000-02-24
GB0004412A GB0004412D0 (en) 2000-02-24 2000-02-24 Proteins and their use for diagnosis and treatment of bipolar affective disorder and unipolar depression
GB0030050 2000-12-08
GB0030050A GB0030050D0 (en) 2000-12-08 2000-12-08 Proteins, genes and their use for diagnosis and treatment of bipolar affective disorder (BAD) and unipolar depression
US25483000P 2000-12-12 2000-12-12
US60254830 2000-12-12
PCT/GB2001/000791 WO2001063294A2 (en) 2000-02-24 2001-02-23 Diagnosis of bipolar affective disorder (bad) and unipolar depression

Publications (1)

Publication Number Publication Date
AU2001233957A1 true AU2001233957A1 (en) 2001-09-03

Family

ID=27255558

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001233955A Abandoned AU2001233955A1 (en) 2000-02-24 2001-02-23 Diagnosis and treatment of bipolar affective disorder
AU2001233957A Abandoned AU2001233957A1 (en) 2000-02-24 2001-02-23 Proteins, genes and their use for diagnosis and treatment of bipolar affective disorder (bad) and unipolar depression

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU2001233955A Abandoned AU2001233955A1 (en) 2000-02-24 2001-02-23 Diagnosis and treatment of bipolar affective disorder

Country Status (3)

Country Link
EP (2) EP1259819A2 (en)
AU (2) AU2001233955A1 (en)
WO (2) WO2001062787A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7314762B2 (en) 2001-11-21 2008-01-01 Nanogen, Inc. Apolipoprotein biopolymer markers indicative of insulin resistance
US7052849B2 (en) * 2001-11-23 2006-05-30 Syn X Pharma, Inc. Protein biopolymer markers predictive of insulin resistance
US20030113808A1 (en) * 2001-12-13 2003-06-19 George Jackowski Apolipoprotein biopolymer markers predictive of alzheimers disease
DE10225144A1 (en) * 2002-05-29 2003-12-18 Immatics Biotechnologies Gmbh Tumor-associated peptides binding to MHC molecules
EP1394549A1 (en) 2002-08-23 2004-03-03 Bayer HealthCare AG Biomarkers for diagnosing Alzheimer's disease
CA2746000C (en) * 2002-08-23 2014-10-21 Bayer Schering Pharma Aktiengesellschaft Biomarkers for diagnosing alzheimer's disease
ATE365798T1 (en) 2003-04-17 2007-07-15 Affectis Pharmaceuticals Ag MEANS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF AFFECTIVE DISORDERS
KR101219519B1 (en) * 2011-05-06 2013-01-09 한국기초과학지원연구원 A method for the diagnosis using lectin
RU2488118C1 (en) * 2011-11-21 2013-07-20 Учреждение Российской Академии Медицинских Наук Научно-Исследовательский Институт Психического Здоровья Сибирского Отделения Рамн Method for prediction of formation of organic personality disorder
CN110361242B (en) * 2019-08-14 2022-01-18 武汉赛维尔生物科技有限公司 Fixing liquid for eyeball tissue and pretreatment method for preparing eyeball tissue slices

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990014363A1 (en) * 1989-05-19 1990-11-29 Amgen Inc. Metalloproteinase inhibitor
CA2243984A1 (en) * 1997-02-13 1998-08-20 Smithkline Beecham P.L.C. Neural cell adhesion molecule splicing variants
US5866412A (en) * 1997-03-27 1999-02-02 Millennium Pharmaceuticals, Inc. Chromosome 18 marker
WO2000056889A2 (en) * 1999-03-23 2000-09-28 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO1999004825A1 (en) * 1997-07-22 1999-02-04 Millennium Pharmaceuticals, Inc. Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders
KR100626475B1 (en) * 1997-10-24 2006-09-20 아방티 파르마 소시에테 아노님 Peptides That Inhibit the Interaction Between Presenilin and Beta-amyloid Peptides or Their Precursors
WO1999035290A1 (en) * 1998-01-08 1999-07-15 Millennium Pharmaceuticals, Inc. Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders
AU3762699A (en) * 1998-04-27 1999-11-16 Pacific Northwest Cancer Foundation (nr-cam) gene, nucleic acids and nucleic acid products for therapeutic and diagnostic uses for tumors
JP2002533058A (en) * 1998-05-12 2002-10-08 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 97 human secreted proteins

Also Published As

Publication number Publication date
WO2001063294A2 (en) 2001-08-30
WO2001062787A1 (en) 2001-08-30
EP1259819A2 (en) 2002-11-27
WO2001063294A3 (en) 2002-04-11
AU2001233955A1 (en) 2001-09-03
EP1259539A1 (en) 2002-11-27

Similar Documents

Publication Publication Date Title
AU2002216273A1 (en) Proteins, genes and their use for diagnosis and treatment of kidney response
AU2003275029A1 (en) Treatment of patients with multiple sclerosis based on gene expression changes in central nervous system tissues
AU3368497A (en) Human dnase i hyperactive variants
AU2003284891A1 (en) A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same
MXPA02011656A (en) Nrg 2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods.
EP2332955A3 (en) Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
EP2253706A3 (en) Antisense modulation of kinesin-like 1 expression
WO2003053340A3 (en) Antisense modulation of connective tissue growth factor expression
EP1248794A4 (en) ANTISENSE MODULATION OF SMAD7 PROTEIN EXPRESSION
WO2001070977A3 (en) Fibroblast growth factor receptor-like molecules and uses thereof
AU2002251366A1 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
CA2406057A1 (en) Methods and compositions for modulating alpha adrenergic receptor activity
AU2001233957A1 (en) Proteins, genes and their use for diagnosis and treatment of bipolar affective disorder (bad) and unipolar depression
AU2002330215A1 (en) Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease
AU2001240909A1 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
WO2003023004A3 (en) Antisense modulation of fibroblast growth factor receptor 3 expression
AU6583700A (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
AU5305000A (en) Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses
NZ504445A (en) Nucleic acid sequences of genes of the high mobility group proteins and their use in treating tumours, vascular disorders and as a contraceptive
AU2001237543A1 (en) Proteins, genes and their use for diagnosis and treatment of schizophrenia
WO2004043394A3 (en) Modulation of huntingtin interacting protein 1 expression
EP2270230A3 (en) Antisense modulation of insulin-like growth factor binding protein 5 expression
AU2001234831A1 (en) Magnetoliposome composition for targeted treatment of biological tissue and associated methods
GB0030050D0 (en) Proteins, genes and their use for diagnosis and treatment of bipolar affective disorder (BAD) and unipolar depression
WO2001089558A3 (en) Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states